Ovid Therapeutics Inc - Asset Resilience Ratio
Ovid Therapeutics Inc (OVID) has an Asset Resilience Ratio of 7.82% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read OVID liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Ovid Therapeutics Inc's Asset Resilience Ratio has changed over time. See Ovid Therapeutics Inc (OVID) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Ovid Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Ovid Therapeutics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.99 Million | 7.82% |
| Total Liquid Assets | $4.99 Million | 7.82% |
Asset Resilience Insights
- Limited Liquidity: Ovid Therapeutics Inc maintains only 7.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ovid Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Ovid Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Ovid Therapeutics Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Ovid Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.05% | $26.77 Million | $92.17 Million | -25.66pp |
| 2023-12-31 | 54.71% | $78.79 Million | $144.03 Million | +0.52pp |
| 2022-12-31 | 54.19% | $84.13 Million | $155.27 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $194.54 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $75.93 Million | -- |
| 2019-12-31 | 43.10% | $34.84 Million | $80.84 Million | +32.58pp |
| 2018-12-31 | 10.52% | $5.01 Million | $47.65 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $89.46 Million | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule dire… Read more